Reply  by Watson, Paul S et al.
calculated number of patients necessary (n 5 17) in this cross-over
trial seems highly underestimated.
In a nearly threefold larger trial of 79 patients from Scandinavia,
the same double-blind, cross-over design was used over two
periods of three months on coenzyme Q10 100 mg/day or placebo.
The beneficial results of this study were presented initially at The
American College of Cardiology Meeting in 1992 (JACC 1992;
19:216A, abstract 774–6) and later published in the Journal of
Cardiac Failure (3). Watson et al. (1) have not included this trial in
their reference list.
In the Scandinavian Multicenter Study, a balanced randomiza-
tion was used with respect to the diagnosis of ischemic versus
nonischemic disease and the treatment with or without an
angiotensin-converting enzyme inhibitor. There was a slight im-
provement on LV ejection fraction at volume load based on the
results from the MUGA scans (p 5 0.025). Maximal exercise
capacity increased slightly but significantly (p 5 0.016) and
coenzyme Q10 mediated a significant decrease in the scoring for
dyspnea (p 5 0.007) and leg fatigue (p 5 0.04) at end-exercise
(using the Borg-scale). According to the scoring from the Quality
of Life Questionnaire, the total score (p 5 0.016), the physical
activity level (p 5 0.048) and the life satisfaction (p 5 0.016)
increased significantly during the coenzyme Q10 period.
During the last 15 years, only 2 of 12 double-blind heart-failure
trials have been “neutral” (i.e., without positive effect or side
effects), whereas the remaining 10 studies have been positive and
statistically significant with respect to improvement in clinical and
or hemodynamic parameters (4). In Watson and colleagues’
“neutral study,” adequate methods to assess myocardial function
were used, but obviously the trial was insufficiently powerful to
confirm or reject the hypothesized increase in LV function.
Svend Aage Mortensen, MD, DSc, FESC
Heart Center
Rigshopitalet
University Hospital of Copenhagen
Copenhagen, Denmark
PII S0735-1097(00)00668-9
REFERENCES
1. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN.
Lack of effect of coenzyme Q on left ventricular function in patients
with congestive heart failure. J Am Coll Cardiol 1999;33:1549–52.
2. Waston PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN.
Lack of effect of coenzyme Q10 on left ventricular function in patients
with congestive heart failure. Proceedings from an International Sym-
posium: Oxidative Pathways in Health and Disease, University of
Sydney, Australia, December 1–4, 1999.
3. Hofman-Bang C, Rehnquist N, Swedberg K, Wiklund I, Åstro¨m H,
for the Q10 Study Group. Coenzyme Q10 as an adjunctive in the
treatment of chronic congestive heart failure. J Card Fail 1995;1:101–7.
4. Overvad K, Diamant B, Holm L, Hølmer G, Mortensen SA, Stender
S. Coenzyme Q10 in health and disease. Eur J Clin Nutr 1999;53:764–
70.
REPLY
We thank Dr. Mortensen for his interest in our study (1). We
assure him that the data we reported on patient demographics are
correct—that over three-quarters of our patients suffered from
dilated cardiomyopathy while the remainder had coronary heart
disease. When we stated that we would require 17 patients in order
to demonstrate an increase in left ventricular ejection fraction from
25% to 30% with a standard deviation (SD) of 5% using 95%
confidence intervals (CI) with a power of 80% (1), we did no more
than calculate the probability that our failure to show such as
change (a negative study) would reflect a true lack of effort.
The design of the Scandinavian study to which Dr. Mortensen
refers (2) was very similar to that of our trial. Despite having nearly
three times as many patients, it also failed to show any significant
difference (p , 0.05) in this primary end point. The study reported
by Permanetter et al. (3) also failed to show any therapeutic effect
of coenzyme Q 10. Meta-analysis of clinical trials of coenzyme
Q 10 treatment of congestive heart failure might be seen as
encouraging but cannot be taken as any more than an argument for
more blinded control studies (4,5).
We agree with Dr. Mortensen that if agents such as coenzyme
Q 10 are to be helpful, this would more likely be demonstrable
early in the course of heart failure. Unfortunately, success in
treating chronic failure with angiotensin-converting enzyme inhib-
itors (6), beta-adrenergic blockers (7), and spironolactone (8)
means that it has become increasingly difficult to recruit patients
for trials of unproven agents until they have been stabilized on
what must now be regarded as standard therapy.
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